PRMT1 acts as a suppressor of MHC-I and anti-tumor immunity
Details
Publication Year 2024-02-23,Volume 43,Issue #3,Page 113831
Journal Title
Cell Reports
Publication Type
Research article
Abstract
Cancer immunotherapies have demonstrated remarkable success; however, the majority of patients do not respond or develop resistance. Here, we conduct epigenetic gene-targeted CRISPR-Cas9 screens to identify epigenomic factors that limit CD8(+) T cell-mediated anti-tumor immunity. We identify that PRMT1 suppresses interferon gamma (Ifnγ)-induced MHC-I expression, thus dampening CD8(+) T cell-mediated killing. Indeed, PRMT1 knockout or pharmacological targeting of type I PRMT with the clinical inhibitor GSK3368715 enhances Ifnγ-induced MHC-I expression through elevated STAT1 expression and activation, while re-introduction of PRMT1 in PRMT1-deficient cells reverses this effect. Importantly, loss of PRMT1 enhances the efficacy of anti-PD-1 immunotherapy, and The Cancer Genome Atlas analysis reveals that PRMT1 expression in human melanoma is inversely correlated with expression of human leukocyte antigen molecules, infiltration of CD8(+) T cells, and overall survival. Taken together, we identify PRMT1 as a negative regulator of anti-tumor immunity, unveiling clinical type I PRMT inhibitors as immunotherapeutic agents or as adjuncts to existing immunotherapies.
Publisher
Cell Press
Keywords
CP: Cancer; CP: Immunology; Prmt1; Stat1; argenine methylation; cancer; immunology
Department(s)
Laboratory Research
Open Access at Publisher's Site
https://doi.org/10.1016/j.celrep.2024.113831
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-04-02 01:27:25
Last Modified: 2024-04-02 01:33:27

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙